Core Viewpoint - The report outlines the findings from the on-site inspection conducted by Huatai United Securities on Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, confirming compliance with various regulatory requirements and internal controls [1][2][3] Group 1: Company Governance - The inspection confirmed that the company governance documents, including business registration files and articles of association, were complete and properly maintained [1] - The company’s board meetings and related resolutions were reviewed, ensuring compliance with execution and disclosure obligations [1][2] Group 2: Internal Control - The internal audit department's structure and operational effectiveness were assessed, with no significant issues found [1][2] - The audit committee's documentation and the execution of the internal audit work plan were also reviewed, confirming adherence to established procedures [1][2] Group 3: Information Disclosure - The company’s information disclosure archives and related supporting documents were examined, ensuring compliance with disclosure management regulations [2] Group 4: Protection of Company Interests - The establishment and execution of mechanisms to protect the company’s interests, particularly regarding related party transactions and external guarantees, were verified [2] Group 5: Use of Raised Funds - The inspection included a review of the bank statements for the special account for raised funds, confirming proper usage in line with disclosed purposes [2] Group 6: Performance Situation - Discussions with management provided insights into the company's operational status and significant changes, with financial statements and major contracts reviewed for accuracy [2] Group 7: Commitment Fulfillment - The commitments made by the company and its shareholders were checked for compliance, with no issues reported [2][3] Group 8: Other Important Matters - Additional inquiries into the company's operational conditions and large fund payment approval processes were conducted, with no significant findings [3]
普蕊斯: 华泰联合证券有限责任公司关于普蕊斯（上海）医药科技开发股份有限公司2025年半年度现场检查报告